Cj0983 Antibody

What is Cj0983 and what organism does it originate from?

Cj0983 is an uncharacterized lipoprotein found in Campylobacter jejuni, specifically identified in the C. jejuni subsp. jejuni serotype O:2 (strain NCTC 11168). C. jejuni is a Gram-negative, spiral-shaped, microaerophilic bacterium that causes gastroenteritis in humans worldwide. The protein has been assigned the UniProt accession number P45492 and encompasses amino acids 18-372 in its recombinant form. This bacterium naturally colonizes the digestive tract of many bird species, particularly poultry, which serves as a primary source of human infection .

What are the key specifications of commercially available Cj0983 antibodies?

Commercial Cj0983 antibodies, such as CSB-PA338203XA01FTH, are typically polyclonal antibodies raised in rabbits against recombinant Campylobacter jejuni subsp. jejuni serotype O:2 (strain ATCC 700819/NCTC 11168) Cj0983 protein. These antibodies are generally available in liquid form containing a storage buffer of 50% glycerol, 0.01M PBS (pH 7.4), and 0.03% Proclin 300 as a preservative. They are purified using antigen affinity methods and belong to the IgG isotype. Researchers should note that these antibodies are specific to C. jejuni strain NCTC 11168 and may require validation for use with other strains .

What applications have been validated for Cj0983 antibodies?

Cj0983 antibodies have been validated primarily for ELISA (Enzyme-Linked Immunosorbent Assay) and Western Blot (WB) applications. These methods allow for the detection and quantification of the Cj0983 protein in research samples. While these are the established applications, researchers should perform validation experiments when applying these antibodies to other techniques or when using samples from different C. jejuni strains than the immunogen strain (NCTC 11168) .

What is the recommended protocol for validating a Cj0983 antibody before experimental use?

A rigorous validation protocol for Cj0983 antibody should follow these steps:

• Cell Line Selection: Identify a cell line expressing high levels of Cj0983 using proteomic databases like PaxDB.

• Generate Knockout Controls: Create CRISPR/Cas9-mediated knockouts (KO) of the cj0983 gene in the selected cell line.

• Immunoblot Validation: Perform Western blot analysis comparing lysates from parental and KO cell lines (50 μg protein loading recommended).

• Signal Verification: Confirm the antibody produces a strong signal in parental lysates that is reduced or absent in KO lysates.

• Cross-reactivity Assessment: Test for non-specific binding or cross-reactivity.

• Additional Validation: For antibodies passing initial screening, conduct further validation through immunoprecipitation and immunofluorescence.

This approach, based on contemporary antibody validation standards, ensures specificity and reliability before proceeding with experimental applications .

What storage conditions maximize the stability and activity of Cj0983 antibodies?

For optimal maintenance of Cj0983 antibody activity, store at -20°C or -80°C immediately upon receipt. Repeated freeze-thaw cycles should be strictly avoided as they can degrade the antibody and reduce its effectiveness. When working with the antibody, prepare aliquots during initial thawing to minimize future freeze-thaw events. The storage buffer (containing 50% glycerol, 0.01M PBS at pH 7.4, and 0.03% Proclin 300 as a preservative) helps maintain stability, but proper temperature conditions remain crucial. For short-term use during experimentation, keep the antibody on ice and return to -20°C or -80°C storage promptly after use .

How should researchers optimize Western blot protocols for Cj0983 detection?

For optimal Western blot detection of Cj0983:

• Sample Preparation: Extract proteins using buffer containing 1% Triton X-100 to capture both cytosolic and membrane-associated proteins.

• Protein Loading: Load 50 μg of protein per lane.

• Gel Selection: Use 5-16% gradient gels for optimal resolution.

• Transfer Verification: Perform Ponceau S staining of nitrocellulose membranes to ensure even loading and transfer.

• Blocking: Block membranes with 5% non-fat milk in TBST for 1 hour at room temperature.

• Primary Antibody Incubation: Dilute Cj0983 antibody (typical working dilution 1:1000, but optimize based on specific antibody) and incubate overnight at 4°C.

• Controls: Include positive controls (C. jejuni NCTC 11168 lysate) and negative controls (knockout cell lysate if available).

• Signal Development: Use enhanced chemiluminescence for detection with appropriate exposure times.

This protocol is based on successful antibody characterization methods and should be optimized for specific research requirements .

How can Cj0983 antibodies be utilized to study C. jejuni pathogenesis and colonization?

Cj0983 antibodies can serve as valuable tools for investigating C. jejuni pathogenesis through several sophisticated approaches:

• Cellular Localization Studies: Immunofluorescence microscopy with Cj0983 antibodies can reveal the spatial distribution of this lipoprotein during different stages of infection, particularly during the formation of C. jejuni-containing vacuoles (CCVs) that enable intracellular survival.

• Host-Pathogen Interaction Analysis: Co-immunoprecipitation experiments using Cj0983 antibodies can identify host proteins that interact with this lipoprotein during colonization and invasion of intestinal epithelial cells.

• Expression Profiling: Quantitative immunoblotting can monitor changes in Cj0983 expression under various environmental conditions that mimic the host environment (bile salts, oxygen limitation, pH changes).

• Functional Blocking Studies: If Cj0983 is involved in adhesion or invasion, blocking antibodies could potentially inhibit these processes in in vitro models.

• Comparative Proteomics: Using Cj0983 antibodies to isolate the protein for mass spectrometry analysis can reveal post-translational modifications that might occur during infection.

These applications could provide insights into whether Cj0983 contributes to the invasive capabilities of C. jejuni, which involve microtubule polymerization and actin-based processes as described in pathogenesis studies .

How does Cj0983 expression correlate with the electron transport capabilities of C. jejuni?

While direct evidence linking Cj0983 to electron transport in C. jejuni is limited in the provided literature, researchers can investigate potential correlations through several methodological approaches:

• Expression Analysis Under Varying Oxygen Conditions: Since C. jejuni is microaerophilic and shows significant adaptations in its electron transport chains under oxygen limitation, researchers can measure Cj0983 expression levels using the validated antibody under different oxygen concentrations.

• Co-localization Studies: Immunofluorescence microscopy using both Cj0983 antibodies and markers for electron transport components (such as cytochrome c) can reveal whether Cj0983 localizes near respiratory complexes.

• Functional Studies in Mutants: Compare Cj0983 expression in wild-type C. jejuni versus mutants with defects in specific electron transport components, such as the novel tetrathionate reductase (TsdA) or twin-arginine translocase (TAT) systems described in the literature.

• Activity Correlation: Measure respiratory enzyme activities (like tetrathionate reduction or thiosulphate oxidation) and correlate with Cj0983 expression levels quantified by immunoblotting.

This approach would be particularly relevant given that C. jejuni shows remarkable adaptability in its electron transport chains, as evidenced by the novel tetrathionate reductase activity and the complex c-type cytochrome system documented in research .

What role might Cj0983 play in C. jejuni's adaptation to oxygen-limited environments?

Based on C. jejuni's known adaptations to oxygen-limited conditions, researchers can investigate Cj0983's potential role through these methodological approaches:

• Expression Profiling: Quantify Cj0983 expression using validated antibodies in C. jejuni cultures grown under strictly controlled oxygen gradients, ranging from microaerobic to oxygen-limited conditions.

• Mutant Phenotype Analysis: Generate cj0983 knockout mutants and examine their growth and survival in oxygen-limited environments compared to wild-type strains, particularly evaluating if they show altered ability to utilize alternative electron acceptors like tetrathionate.

• Protein Interaction Studies: Use co-immunoprecipitation with Cj0983 antibodies followed by mass spectrometry to identify potential protein-protein interactions with known components of anaerobic respiratory pathways, such as the fumarate reductase (Mfr) or the novel tetrathionate reductase (TsdA).

• Structural Analysis: If Cj0983 contains redox-active domains, examine whether it undergoes structural changes in response to oxygen limitation that might be detectable through conformation-specific antibodies.

These approaches could reveal whether Cj0983 contributes to the sophisticated adaptations that C. jejuni employs during oxygen-limited growth, such as the up-regulation of siderophore-based iron acquisition systems and the modulation of anaerobic electron transport pathways documented in transcriptome studies .

What approaches can address cross-reactivity challenges when using Cj0983 antibodies?

To address potential cross-reactivity challenges with Cj0983 antibodies, researchers should implement a multi-faceted validation strategy:

• Knockout Controls: Generate CRISPR/Cas9-mediated knockouts of the cj0983 gene to create the gold standard negative control for antibody specificity testing.

• Multi-strain Testing: Test the antibody against lysates from multiple Campylobacter species and strains to evaluate cross-reactivity within the genus.

• Peptide Competition Assays: Pre-incubate the antibody with purified Cj0983 protein or peptide fragments before immunodetection to confirm binding specificity.

• Western Blot Profiling: Conduct detailed band analysis on Western blots, comparing observed band patterns with predicted protein sizes and identifying any unexpected bands that might indicate cross-reactivity.

• Mass Spectrometry Validation: For immunoprecipitation applications, verify the identity of pulled-down proteins through mass spectrometry to confirm antibody specificity.

• Sequential Immunodepletion: In complex samples, perform sequential immunodepletion with different antibodies to verify target specificity.

How can researchers determine the optimal antibody concentration for different experimental techniques?

Determining optimal antibody concentration requires systematic titration for each experimental technique:

For Western Blotting:

• Prepare a dilution series (typically 1:500 to 1:5000) of the Cj0983 antibody.

• Test each dilution against a constant amount of positive control lysate (C. jejuni NCTC 11168).

• Evaluate signal-to-noise ratio at each concentration.

• Select the lowest concentration that provides clear, specific signal with minimal background.

For ELISA:

• Perform a checkerboard titration with varying concentrations of both capture antibody and detection antibody.

• Calculate signal-to-noise ratios for each combination.

• Generate a titration curve to identify the optimal working concentration.

For Immunofluorescence:

• Test a range of antibody dilutions (typically 1:50 to 1:500).

• Compare specific signal intensity to background fluorescence.

• Select the dilution that maximizes specific labeling while minimizing non-specific background.

For all techniques, include appropriate negative controls (knockout samples or isotype controls) to assess non-specific binding at each concentration tested .

What technical considerations are important when using Cj0983 antibodies for immunoprecipitation studies?

For successful immunoprecipitation (IP) using Cj0983 antibodies, consider these technical aspects:

• Lysis Buffer Optimization: Since Cj0983 is a lipoprotein, use buffers containing 1% Triton X-100 or similar detergents to efficiently solubilize membrane-associated proteins while maintaining native protein conformation.

• Antibody Binding Conditions: Determine optimal antibody-to-lysate ratios through preliminary experiments. Typically start with 2-5 μg antibody per 500-1000 μg of total protein lysate.

• Pre-clearing Step: Implement a pre-clearing step using control IgG and protein A/G beads to reduce non-specific binding.

• Cross-linking Consideration: For challenging interactions, consider cross-linking the antibody to beads using dimethyl pimelimidate (DMP) to prevent antibody contamination in the eluted sample.

• Negative Controls: Always include a parallel IP with isotype-matched control IgG to identify non-specific binding.

• Validation of IP Results: Confirm the identity of immunoprecipitated proteins through Western blotting and/or mass spectrometry.

• Native vs. Denaturing Conditions: For co-IP studies to identify interaction partners, maintain native conditions; for studies focused solely on Cj0983, denaturing conditions may yield higher specificity.

• Elution Strategy: Compare acidic elution (which may better preserve binding partners) with denaturing elution (which provides higher recovery but may disrupt interactions) to determine the optimal approach for your specific research question .

How can active learning approaches improve antibody-antigen binding predictions for Cj0983 research?

Active learning methodologies can significantly enhance Cj0983 antibody-antigen binding predictions through these implementation strategies:

• Iterative Library Screening: Begin with a small subset of labeled antibody-antigen pairs, then employ an active learning algorithm to select the most informative additional pairs for experimental testing, reducing the total number of experiments needed by up to 35%.

• Uncertainty Sampling: Prioritize measurements for Cj0983 variants where the model's prediction confidence is lowest, focusing experimental resources on the most informative data points.

• Diversity-Based Selection: Select Cj0983 variants that maximize sequence diversity to ensure broad coverage of epitope space.

• Transfer Learning Implementation: Apply knowledge gained from related antigens to improve prediction accuracy for novel Cj0983 variants, particularly valuable for out-of-distribution predictions.

• Balanced Batch Selection: When selecting batches for experimental validation, balance exploration (testing diverse variants) with exploitation (refining predictions in promising regions).

These approaches can accelerate learning by approximately 28 steps compared to random selection strategies, making the experimental process substantially more efficient while maintaining prediction accuracy. This is particularly valuable for out-of-distribution scenarios where test antibodies and antigens differ from training data .

What potential role might Cj0983 play in the development of vaccines against C. jejuni?

Exploring Cj0983's potential as a vaccine candidate requires systematic investigation through these research approaches:

• Antigenicity Assessment: Use purified recombinant Cj0983 protein and validated antibodies to evaluate humoral immune responses in infected hosts or animal models, measuring antibody titers and specificity.

• Conservation Analysis: Perform bioinformatic analysis of Cj0983 sequence conservation across clinically relevant C. jejuni strains to determine if it contains conserved epitopes suitable for broad-spectrum protection.

• Accessibility Verification: Use Cj0983 antibodies in immunofluorescence or flow cytometry of intact bacteria to confirm surface exposure and accessibility to immune recognition.

• Functional Antibody Screening: Test whether Cj0983 antibodies demonstrate bactericidal or opsonizing activity in vitro, indicating potential protective mechanisms.

• Animal Model Testing: Evaluate recombinant Cj0983-based immunogens in appropriate animal models, using validated antibodies to monitor immune responses and correlate with protection levels.

• Epitope Mapping: Identify immunodominant epitopes through peptide arrays and competition assays with the validated antibody to guide rational epitope-focused vaccine design.

These methodological approaches would help determine whether Cj0983's properties as an uncharacterized lipoprotein make it suitable for inclusion in subunit or conjugate vaccine formulations targeting C. jejuni, which remains a significant cause of bacterial gastroenteritis worldwide .

How might Cj0983 antibodies help elucidate the transition of C. jejuni from spiral to coccal forms under atmospheric oxygen?

Cj0983 antibodies can serve as powerful tools for investigating C. jejuni's morphological transition from spiral to coccal forms under atmospheric oxygen through these methodological approaches:

• Time-Course Immunofluorescence: Track Cj0983 localization during morphological transformation using immunofluorescence microscopy with validated antibodies, capturing images at defined intervals after oxygen exposure.

• Co-localization Studies: Employ dual-labeling with Cj0983 antibodies and markers for cell division proteins or cytoskeletal elements to investigate potential redistribution during the transition.

• Quantitative Western Blotting: Monitor changes in Cj0983 protein levels throughout the transformation process, correlating expression patterns with morphological stages.

• Protease Accessibility Assays: Use protease protection assays with subsequent Cj0983 immunoblotting to determine if protein topology or membrane association changes during the transition.

• Immunoelectron Microscopy: Apply gold-labeled Cj0983 antibodies for high-resolution localization studies at different stages of the morphological transition.

• Protein-Protein Interaction Profiling: Perform immunoprecipitation with Cj0983 antibodies followed by mass spectrometry at different transition timepoints to identify changing interaction partners.

These approaches could reveal whether Cj0983 plays a structural or signaling role in C. jejuni's morphological adaptation to atmospheric oxygen, a key survival mechanism that allows this pathogen to persist in the environment despite its microaerophilic nature .

What are the key specifications of validated Cj0983 antibodies for research applications?

Table 1: Technical Specifications of Commercial Cj0983 Antibody

This comprehensive specification table provides researchers with the essential technical parameters needed to effectively integrate Cj0983 antibodies into experimental protocols .

What methodological approaches are recommended for validating Cj0983 antibody specificity?

Table 2: Validation Protocol Framework for Cj0983 Antibodies

This systematic validation framework ensures comprehensive assessment of Cj0983 antibody specificity across multiple technical platforms, allowing researchers to proceed with confidence in experimental applications .

What optimization strategies maximize signal-to-noise ratio in Cj0983 antibody applications?

Table 3: Optimization Parameters for Cj0983 Antibody Applications

This optimization table provides researchers with systematic parameter ranges and evaluation metrics to maximize specificity and sensitivity when working with Cj0983 antibodies across multiple experimental platforms .

What emerging technologies could enhance the specificity and sensitivity of Cj0983 antibody applications?

Several cutting-edge technologies show promise for enhancing Cj0983 antibody applications:

• Single B-cell Antibody Sequencing: This technology enables isolation of B cells from immunized animals followed by sequencing of antibody genes to create monoclonal antibodies with potentially higher specificity than current polyclonal options for Cj0983.

• Nanobody Development: Engineering of single-domain antibodies (nanobodies) against Cj0983 could provide superior access to conformational epitopes and improved penetration in complex samples.

• Aptamer Complementation: Developing DNA or RNA aptamers that recognize different epitopes than the antibody could create dual-recognition systems with dramatically improved specificity.

• Proximity Ligation Assays: Combining Cj0983 antibodies with oligonucleotide tags would enable super-resolution detection and quantification through rolling circle amplification, significantly enhancing sensitivity.

• CRISPR Display Systems: CRISPR-based labeling of Cj0983 could complement antibody approaches for live-cell imaging applications with enhanced specificity.

• Machine Learning Integration: Implementing predictive models using active learning approaches could optimize antibody-antigen binding predictions and reduce required experimental testing by up to 35%, particularly valuable for out-of-distribution scenarios.

These advanced technologies represent promising avenues for overcoming current limitations in Cj0983 detection and characterization .

How might understanding Cj0983's role advance our knowledge of C. jejuni pathogenesis?

Elucidating Cj0983's function could significantly advance our understanding of C. jejuni pathogenesis through these potential research avenues:

• Host-Pathogen Interface: As a lipoprotein, Cj0983 may interact with host pattern recognition receptors, potentially modulating immune responses during infection. Characterizing these interactions could reveal immune evasion mechanisms.

• Environmental Adaptation: Given C. jejuni's transition between hosts (poultry to humans) and environments (microaerobic to atmospheric), Cj0983 might function in sensing or responding to these changes, possibly coordinating gene expression programs needed for survival.

• Bacterial Physiology: Examining potential links between Cj0983 and C. jejuni's unique electron transport capabilities could reveal how this pathogen generates energy in the intestinal environment, where oxygen is limited.

• Colonization Mechanisms: Investigating whether Cj0983 interacts with the complex machinery involved in microtubule polymerization and actin-based processes during epithelial cell invasion could uncover new aspects of C. jejuni's cellular invasion strategy.

• Biofilm Formation: Determining if Cj0983 contributes to community behaviors like biofilm formation could explain persistence in environmental reservoirs and resistance to environmental stresses.

These investigations would fill critical knowledge gaps regarding this uncharacterized lipoprotein, potentially identifying new therapeutic targets against this leading cause of bacterial gastroenteritis worldwide .

What potential exists for developing Cj0983-based diagnostic tools for C. jejuni detection?

The development of Cj0983-based diagnostics presents several promising research avenues:

• Point-of-Care Immunoassays: Validated Cj0983 antibodies could be incorporated into lateral flow assays or microfluidic devices for rapid detection of C. jejuni in clinical or food safety applications, with potential sensitivity improvements over current methods.

• Multiplexed Detection Platforms: Combining Cj0983 antibodies with antibodies against other C. jejuni markers in multiplex assays could enhance specificity while maintaining sensitivity, reducing false positives in complex samples.

• Biosensor Development: Immobilizing Cj0983 antibodies on electrochemical or optical biosensor surfaces could enable real-time, label-free detection with potentially lower detection limits than conventional methods.

• Aptamer-Antibody Hybrid Systems: Complementing Cj0983 antibodies with target-specific aptamers could create dual-recognition platforms with enhanced specificity for detecting C. jejuni in complex food matrices or environmental samples.

• CRISPR-Based Detection: Coupling Cj0983 antibody capture with CRISPR-Cas detection systems could provide highly sensitive nucleic acid detection capabilities with the specificity of immunocapture.

• Machine Learning Integration: Incorporating active learning algorithms could optimize Cj0983 antibody-based detection systems by predicting binding affinities and cross-reactivity, potentially reducing false results by up to 35% compared to conventional approaches.